Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Accounts Payable
Bavarian Nordic A/S
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Accounts Payable
kr1B
|
CAGR 3-Years
58%
|
CAGR 5-Years
56%
|
CAGR 10-Years
33%
|
|
|
Genmab A/S
CSE:GMAB
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Accounts Payable
kr254.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
35%
|
CAGR 10-Years
30%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Accounts Payable
€96.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
28%
|
CAGR 10-Years
34%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Accounts Payable
kr5.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
Saniona AB
STO:SANION
|
Accounts Payable
kr17.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
23%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Accounts Payable?
Accounts Payable
1B
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Accounts Payable amounts to 1B DKK.
What is Bavarian Nordic A/S's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
33%
Over the last year, the Accounts Payable growth was 10%. The average annual Accounts Payable growth rates for Bavarian Nordic A/S have been 58% over the past three years , 56% over the past five years , and 33% over the past ten years .
You don't have any saved screeners yet